Corcept Therapeutics stops depression drug trial

[Reuters] – Corcept Therapeutics Inc said it would stop a late-stage trial of its drug for depression after an interim analysis suggested the study was unlikely to be successful. The analysis of data from the first 226 patients enrolled in the trial show more

View todays social media effects on CORT

View the latest stocks trending across Twitter. Click to view dashboard

See who Corcept is hiring next, click here to view